All Stories

  1. Liquid biopsy tracking of lung tumor evolutions over time

    Article • Expert Review of Molecular Diagnostics, October 2019, Taylor & Francis

    Dr Alessandro Russo, Professor VINCENZO ADAMO, francesco pepe

  2. Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel

    Article • Journal of Cellular Physiology, April 2018, Wiley

    Professor VINCENZO ADAMO, Dr Alessandro Russo

  3. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer

    Article • Oncotarget, August 2017, Impact Journals, LLC

    Professor VINCENZO ADAMO

  4. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer

    Article • Expert Opinion on Pharmacotherapy, May 2017, Taylor & Francis

    Dr Alessandro Russo, Professor VINCENZO ADAMO

  5. Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al

    Article • Breast Cancer Targets and Therapy, August 2016, Dove Medical Press

    Professor Giovanni Tuccari, Professor VINCENZO ADAMO, Dr Antonio Ieni

  6. Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer

    Article • OncoTargets and Therapy, July 2016, Dove Medical Press

    Professor VINCENZO ADAMO, Dr Alessandro Russo

  7. Correction: Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

    Article • PLoS ONE, July 2015, PLOS

    Professor VINCENZO ADAMO

  8. Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) Patients

    Article • PLoS ONE, June 2015, PLOS

    Professor VINCENZO ADAMO

  9. Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases

    Article • OncoTargets and Therapy, February 2015, Taylor & Francis

    Professor VINCENZO ADAMO, Dr Alessandro Russo

  10. The Risk of Toxicities from Trastuzumab, Alone or in Combination, in an Elderly Breast Cancer Population

    Article • Oncology, January 2014, Karger Publishers

    Professor VINCENZO ADAMO

  11. Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement

    Article • Cancer Biology & Therapy, May 2012, Taylor & Francis

    Professor VINCENZO ADAMO

  12. Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients

    Article • Journal of Cellular Biochemistry, April 2012, Wiley

    Professor VINCENZO ADAMO

  13. Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives

    Article • Cancer Biology & Therapy, February 2009, Taylor & Francis

    Professor VINCENZO ADAMO